http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2003523357-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-6561 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-6561 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-305 |
| filingDate | 2001-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2003-08-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2003523357-A |
| titleOfInvention | Pyrido [2,3-d] pyrimidine-2,7-diamine kinase inhibitor |
| abstract | (57) [Summary]nFormula (I) wherein R: 2 , R 7 , R 13 , R 14 And R 15 Are independently hydrogen or (un) substituted lower alkyl, (un) substituted lower alkenyl, (un) substituted lower alkynyl or (un) substituted-(CH 2 ) n R 12 And R Five Is halogen, cyano, nitro, -R 9 , -NR 9 R Ten Or -OR 9 And R 6 Is halogen, cyano, nitro, -R 9 , -NR 9 R Ten , -OR 9 , -CO 2 R 9 , -COR 9 , -CONR 9 R Ten , -NR 9 COR Ten , (Un) substituted lower alkenyl, or (un) substituted lower alkynyl; R 8 Is -CO 2 R 13 , -COR 13 , -CONR 13 R 14 , -CSNR 13 R 14 , -C (NR 13 ) NR 14 R 15 , -SO Three R 13 , -SO 2 R 13 , -SO 2 NR 13 R 14 , -PO Three R 13 R 14 , -POR 13 R 14 , -PO (NR 13 R 14 ) 2 And R 9 And R Ten Are independently hydrogen or (un) substituted lower alkyl; R 11 Is a heteroaryl or heterocyclic group; R 12 Is a cycloalkyl, heterocycle, aryl, or heteroaryl group; and n is 0, 1, 2, or 3. These compounds and their pharmaceutical compositions are useful for treating cell proliferative disorders, such as cancer and restenosis. These compounds are potent inhibitors of cdks and growth factor mediated kinases. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019510822-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2008518883-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2012510481-A |
| priorityDate | 2000-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 645.